We are excited to announce that CD38 has been selected as Clovertex’s Target of the Month for June....
We are excited to announce that Protective Antigen has been selected as Clovertex’s Target of the Month for July. Protective Antigen is a critical component of the anthrax toxin and plays a vital role in the development of anthrax vaccines, such as BioThrax, which protect against the bacterial infection caused by Bacillus anthracis.
This spotlight on Protective Antigen comes following the recent news of Emergent BioSolutions securing a 5-year, $235.8 million contract with the U.S. Department of Defense to supply the BioThrax anthrax vaccine to various branches of the United States military. This procurement underscores the continued need for protective measures against anthrax exposure, particularly for military personnel at high risk. Protective Antigen remains a key focus for vaccine research and development, ensuring long-term protection and national defense preparedness.
The Protein Imager rendering displays the crystal structure of the anthrax toxin protective antigen channel bound to edema factor (PDB entry 6UZB).
About Clovertex
Clovertex is an industry leader specializing in meeting the scientific IT needs of pharmaceutical companies, with a robust focus on cloud-based or on-premises cryo-EM processing. As an Advanced Tier Services Partner with Amazon Web Services (AWS), Clovertex leverages its comprehensive expertise to architect, build, automate, and manage software applications designed to meet specific research needs. Our all-encompassing solutions are meticulously tailored to streamline the complex processes associated with pharmaceutical research, underscoring our commitment to innovation, efficiency, and customer satisfaction. By integrating state-of-the-art technology with deep scientific understanding, Clovertex paves the way in optimizing the intersection of information technology and pharmaceutical development.
Useful links
1. Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences
2. Clovertex website
